title: [In vitro cytotox icity effects of cocultured DC-C IK cells combined with sorafenib against hepa to cellular carcinoma].
abstract: OBJECTIVE
  To investigate the in vitro inhibitory effects of DC(dendritic cell)-CIK (cytokine-induced killer cell) cocultured cells combined with sorafenib against hepatocellular carcinoma cell line BEL27402.
  
  
  METHODS
  DC and CIK cells were generated in vitro by stimulating human peripheral blood mononuclear cells with different cytokines, and then they were cocultured. The cytotoxicity of DC-CIK cocultured cells (DC-CIK) combined with sorafenib against BEL-7402 cells was determined by CCK8 kit. The apoptosis of BEL27402 cells was measured by Annexin V-FITC Kit.
  
  
  RESULTS
  The cytotoxicity rate of BEL27402 cells in DC-CIK +sorafenib group was significantly higher than those in the other there groups, with cytotoxicity rate in DC-CIK + sorafenib group being (72.24 ± 2.42)% , which was 1.8 times that in DC-CIK group, 2.1 times that in sorafenib group , and 1.6 times that in CIK group(P < 0.01). The apoptosis rate of BEL-7402 cells in DC-CIK + sorafenib group was significantly higher than those in the sorafenib and DC-CIK groups, with the apop tosis rate in DC-CIK + sorafenib group being (77.36 ± 1.92)% (P < 0.05).
  
  
  CONCLUSIONS
  DC-CIK cocultured cells combined with sorafenib can inhibit the growth of hepatocellular carcinoma cell line BEL-7402 in vitro. Molecular targeting therapy combined with immunotherapy may be a new way for the comprehensive treatment of hepatocellular carcinoma.
authors.affiliation: Hepatobiliary & Enteric Surgery Research Center, Central South University, Changsha 410000, China.
authors.forename: Dan
authors.initials: D
authors.lastname: Zhang
authors.forename: Jian-tai
authors.initials: JT
authors.lastname: He
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology; D001557:Benzenesulfonates / Q000494:pharmacology*; D006528:Carcinoma, Hepatocellular / Q000276:immunology / Q000473:pathology* / Q000628:therapy*; D045744:Cell Line, Tumor; D049109:Cell Proliferation; D018920:Coculture Techniques; D055612:Cytokine-Induced Killer Cells / Q000276:immunology* / Q000378:metabolism; D003602:Cytotoxicity, Immunologic / Q000187:drug effects / Q000276:immunology; D003713:Dendritic Cells / Q000276:immunology / Q000378:metabolism; D006801:Humans; D016219:Immunotherapy, Adoptive; D008113:Liver Neoplasms / Q000276:immunology / Q000473:pathology* / Q000628:therapy*; D051379:Mice; D008819:Mice, Nude; D058990:Molecular Targeted Therapy; D009536:Niacinamide / Q000031:analogs & derivatives; D010671:Phenylurea Compounds; D011725:Pyridines / Q000494:pharmacology*; D000077157:Sorafenib
chemical_list: D000970:Antineoplastic Agents; D001557:Benzenesulfonates; D010671:Phenylurea Compounds; D011725:Pyridines; D009536:Niacinamide; D000077157:Sorafenib